


RealRate

PHARMACEUTICAL 2021

Kura Oncology Inc. Rank 26 of 402







RealRate

Kura Oncology Inc. Rank 26 of 402

The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Kura Oncology Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 281%, being 234% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	637,292
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,024
Liabilities, Non-Current	10,283
Other Assets	7,899
Other Compr. Net Income	-285
Other Expenses	0
Other Liabilities	0
Other Net Income	2,274
Other Revenues	0
Property and Equipment	2,021
Research and Development	60,397
Selling, General and Administrative Expense	31,502

Output Variable	Value in 1000 USD
Assets	647,212
Liabilities	36,307
Expenses	91,899
Revenues	0
Stockholders Equity	610,905
Net Income	-89,625
Comprehensive Net Income	-89,768
Economic Capital Ratio	281%

